Dov Grossman is an accomplished trial lawyer with over 15 years of experience litigating biopharmaceutical patent disputes, including as lead counsel.  Dov’s educational background is in chemistry—with an emphasis on medical chemistry—and he has relied on that experience to successfully represent some of the world’s largest innovator pharmaceutical companies in a wide variety of patent disputes, including for multiple billion-dollar products.  Dov has extensive experience litigating Hatch-Waxman cases, both in the district courts and on appeal.  He has also litigated brand v. brand patent disputes between innovator companies, and has handled numerous inter partes review proceedings before the PTAB.

In addition to pharmaceutical-related matters, Dov has litigated patent cases in the medical device and telecommunications industries.  He also has advised clients on the negotiation of patent licensing agreements, including as the lead outside attorney handling the negotiations.

Dov currently serves as a member of the firm’s Associate Evaluation Committee.

Dov, who speaks Hebrew as well as English, grew up in Los Angeles.  Dov earned his J.D., with honors, from the University of Chicago, where he was articles editor for The University of Chicago Law Review and a member of the Order of the Coif.  Dov clerked for Judge William C. Bryson of the U.S. Court of Appeals for the Federal Circuit.  He received his A.B. in chemistry, magna cum laude, from Harvard University in 1997, and an M.Sc. in chemistry from the Weizmann Institute of Science in 1999.  Aspects of his Weizmann research were published in Letters in Peptide Science in 2002 (“Potentiating Vanadium-Evoked Glucose Metabolism by Novel Hydroxamate Derivatives”).  Dov joined Williams & Connolly in 2004.

Representative Experience

  • Co-lead trial counsel in a Hatch-Waxman trial in the District of Delaware relating to Bayer’s erectile dysfunction medication vardenafil (marketed as Levitra® and Staxyn®).  The Court issued a decision in favor of Bayer on its compound patent at the close of trial.
  • Trial counsel in Hatch-Waxman litigation related to Eli Lilly’s Alimta® product, resulting in multiple victories for the patentee that were upheld on appeal.  Dov has also litigated multiple inter partes review proceedings related to Alimta®, resulting in two final written decisions of the Patent Trial and Appeals Board upholding validity.  The decisions were affirmed on appeal.
  • Trial counsel for Bayer in a Hatch-Waxman case involving the compound patent for the factor Xa inhibitor Xarelto®, which resulted in a judgment in favor of Bayer that was not appealed.  Dov was also lead counsel in two sets of inter partes review challenges to patents protecting Xarelto®, both of which were resolved in Bayer’s favor—in one set of proceedings, the petitions were withdrawn after Bayer submitted its preliminary responses, and in the other proceeding the Board denied institution.
  • Counsel for AstraZeneca in brand v. brand patent litigation and co-pending inter partes review proceedings related to anti-diabetes treatments.
  • Trial counsel for two Hatch-Waxman trials related to moxifloxacin, the antibiotic active ingredient in Bayer’s Avelox® product and Alcon’s Vigamox® eye drops.  Both cases were resolved in favor of the patentee.
  • Counsel for Eli Lilly, Daiichi Sankyo, and Ube Industries in Hatch-Waxman litigation and co-pending inter partes review proceedings involving the anti-platelet medication Effient®.
  • Representing a client in a major international patent licensing arbitration, which was tried before a three-member panel.
  • Lead outside counsel negotiating a portfolio cross-license agreement between suppliers of electronics components.
  • Counsel for Bayer in Hatch-Waxman litigation and an inter partes review proceeding involving the anti-cancer medication Stivarga®.
  • Counsel for AstraZeneca in brand v. brand patent litigation related to the anti-cancer medication Calquence®.
  • Counsel for Bayer in multiple Hatch-Waxman cases involving the anti-cancer medication Nexavar®.
  • Counsel for Alcon in Hatch-Waxman litigation involving Travatan Z® eye drops.

Education

Clerkships

Admissions

back to top